Allergy Therapeutics PLC Directorate Change (2838W)

TIDMAGY

RNS Number : 2838W

Allergy Therapeutics PLC

08 February 2017

8 February 2017

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Directorate Change

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Mr Jeff Barton to the Company's Board as a Non-Executive Director, nominated by Abbott Laboratories, Inc. ("Abbot", NYSE: ABT) in replacement of Mr Jean-Yves Pavee who retires from the Board, both effective after close of business 7 February 2017.

Jeff Barton currently serves as Vice President, Licensing and Acquisitions, at Abbott. During his time in this role, Abbott has executed several strategically important transactions including the acquisition of St. Jude Medical, CFR Pharmaceuticals and Veropharm. He has served Abbott since joining in 1990 in the Financial Development Training program, and during his career has held a variety of financial management positions across Abbott's businesses, including in Diagnostics, Nutrition and Pharmaceuticals. He previously served as Divisional Vice President and Controller for Abbott's North American Nutrition Business and as Area Finance Director for its Asian, African, and Middle Eastern Pharmaceutical unit. Mr Barton holds a degree in accounting from Indiana University, and a Masters of Management from the Northwestern University Kellogg Graduate School of Management.

Peter Jensen, Chairman of Allergy Therapeutics, commented: "We are pleased to welcome Jeff to the Board. He brings extensive commercial experience, particularly in the United States, which will be valuable to our Company as we continue to execute our global strategy. We also wish to take this opportunity to thank Jean-Yves for his contribution and support to Allergy Therapeutics since 2014."

Jeffery Glen Barton, age 48, has no current or prior directorships in the past five years. Allergy Therapeutics confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies.

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focused on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUGUBCPUPMPGM

(END) Dow Jones Newswires

February 08, 2017 02:00 ET (07:00 GMT)